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Perturbation methods add variation terms to a known experimental solution of one problem to approach a solution for a related
problemwithout known exact solution.One problemof this type in immunology is the prediction of the possible action of epitope of
one peptide after a perturbation or variation in the structure of a known peptide and/or other boundary conditions (host organism,
biological process, and experimental assay). However, to the best of our knowledge, there are no reports of general-purpose
perturbation models to solve this problem. In a recent work, we introduced a new quantitative structure-property relationship
theory for the study of perturbations in complex biomolecular systems. In this work, we developed the first model able to classify
more than 200,000 cases of perturbations with accuracy, sensitivity, and specificity >90% both in training and validation series.
The perturbations include structural changes in >50000 peptides determined in experimental assays with boundary conditions
involving >500 source organisms, >50 host organisms, >10 biological process, and >30 experimental techniques. The model may
be useful for the prediction of new epitopes or the optimization of known peptides towards computational vaccine design.
1. Introduction
National Institute of Allergy and InfectiousDiseases (NIAID)
supported the launch, in 2004, of the Immune Epitope Data-
base (IEDB), http://www.iedb.org/ [1–4]. The IEDB system
withdrew information from approximately 99% of all papers
published to date that describe immune epitopes. In doing
so, IEDB system analyses over 22 million PubMed abstracts
and subsequently curated ≈13 K references, including ≈7K
manuscripts about infectious diseases,≈1 K about allergy top-
ics, ≈4K about autoimmunity, and 1 K about transplant/allo-
antigen topics [5]. IEDB lists a huge amount of information
about the molecular structure as well as the experimental
conditions (𝑐
𝑖𝑗
) in which different 𝑖th molecules were deter-
mined to be immune epitopes or not.This explosion of infor-
mation makes necessary both query/display functions for
retrieval of known data from IEDB as well predictive tools for
new epitopes. Salimi et al. [5] reviewed advances in epitope
analysis and predictive tools available in the IEDB. In fact,
IEDB analysis resource (IEDB-AR: http://tools.iedb.org/) is a
collection of tools for prediction of molecular targets of T-
and B-cell immune responses (i.e., epitopes) [6, 7].
On the other hand, Quantitative Structure-Activity/Prop-
erty Relationships (QSAR/QSPR) techniques are useful tool
to predict newdrugs, RNA, drug-protein complexes, and pro-
tein-protein complexes. In general, QSAR/QSPR-like meth-
ods transform molecular structures into numeric molecular
descriptors (𝜆
𝑖
) in a first stage and later fit a model to pre-
dict the biological process. For example, DRAGON [8–10],
CODESSA [11, 12],MOE [13], TOPS-MODE [14–17], TOMO-
COMD [18, 19], and MARCH-INSIDE [20] are among the
most used softwares to calculate molecular descriptors based
on quantum mechanics (QM) and/or graph theory [21–27].
The software STATISTICA [28] and WEKA [29] are often
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used to performmultivariate statistics and/or machine learn-
ing (ML) analysis in order to preprocess data and later fit
the final QSAR/QSPR model using techniques like princi-
pal component analysis (PCA), linear discriminant analysis
(LDA), support vector machine (SVM), or artificial neural
networks (ANN) [28].
QSAR/QSPRmodels are also important in immunoinfor-
matics to predict the propensity of different molecular struc-
tures to play different roles in immunological processes.They
include skin vaccine adjuvants and sensitizers [30–38], drugs
and their activity/toxicity protein targets in the immune
system [39], and epitopes [40–49]. Moreover, Reche and
Reinherz [50] implemented PEPVAC (promiscuous epitope-
based vaccine), a web server for the formulation of multi-
epitope vaccines that predict peptides binding to five distinct
HLA class I supertypes (A2, A3, B7, A24, and B15). PEPVAC
can also identify conserved MHC ligands, as well as those
with a C-terminus resulting from proteasomal cleavage. The
Dana-Farber Cancer Institute hosted the PEPVAC server at
the site http://immunax.dfci.harvard.edu/PEPVAC/. To close
with a last example, Lafuente and Reche [51] reviewed the
available methods for predicting MHC-peptide binding and
discussed their most relevant advantages and drawbacks.
In many complex QSPR-like problems in immunoinfor-
matics, like in other areas, we know the exact experimental
result (known solution) of the problem, but we are interested
in the possible result obtained after a change (perturbation)
on one or multiple values of the initial conditions of the
experiment (new solution). For instance, we often know, for
large collections of 𝑖th molecules (𝑚
𝑖
), organic compounds,
drugs, xenobiotics, and/or peptide sequences, the efficiency
of the compound 𝜀(𝑐
𝑖𝑗
) as adjuvant, action as epitope, immun-
otoxicity, and/or the interaction (affinity, inhibition, etc.) with
immunological targets. In addition, we often known for each
molecule the exact conditions (𝑐
𝑖𝑗
) of assay for the initial
experiment including structure of the molecule 𝑚
𝑖
(drug,
adjuvant, and sequence of the peptide), source organism (so),
host organism (ho), immunological process (ip), experimen-
tal technique (tq), concentration, temperature, time, solvents,
and coadjuvants. This is the case of big data retrieved from
very large databases like IEDB [1–4] and CHEMBL [52].
However, we do not know the possible result of the experi-
ment if we change at least one of these conditions (perturba-
tion). We refer to small changes or perturbations in both
structure and condition for input or output variables. It
means that we include changes in ho, so, ip, and tq, changes of
the compound by one analogue compound with similar
structure, changes in the sequence of the epitope (artificial by
organic synthesis or natural mutations), and polarity of the
solvent or coadjuvants. In these cases, we could use a per-
turbation theory model to solve the QSAR/QSPR problem.
Perturbation theory includes methods that add “small” terms
to a known solution of a problem in order to approach a
solution to a related problemwithout known solution. Pertur-
bation models have been widely used in all branches of
science from QM to astronomy and life sciences including
chaos or “butterfly effect,” Bohr’s atomic theory, Heisenberg’s
mechanics, Zeeman’s and Stark’s effects, and other models
with applications in like protein spectroscopy and others [53–
57]. In a very recent work Gonzalez-Diaz et al. [58] formu-
lated a general-purpose perturbation theory or model for
multiple-boundaryQSPR/QSARproblems. However, there is
not report in the immunoinformatics literature of a general
QSPR perturbation model for IEDB B-epitopes. Here we
report the first example of QSPR-perturbation model for B-
epitopes reported in IEDB able to predict the probability of
occurrence of an epitope after a perturbation in the sequence,
the experimental technique, the exposition process, and/or
the source or host organisms.
2. Materials and Methods
2.1. Molecular Descriptors for Peptides. We calculated the
molecular descriptors of the structure of peptides using the
softwareMARCH-INSIDE (MI) based on the algorithmwith
the same name [59]. The MI approach uses a Markov Chain
method to calculate the 𝑘th mean values of different physico-
chemical molecular properties 𝜆(𝑚
𝑖
) for 𝑖th molecules (𝑚).
These 𝜆(𝑚
𝑖
) values are calculated as an average of 𝑘𝜆(𝑚𝑖)
values for all atoms placed at topological distance 𝑑 ≤ 𝑘;
which are in turn the means of atomic properties (𝜆
𝑗
) for all
atoms in the molecule and its neighbors placed at 𝑑 = 𝑘.
For instance, it is possible to derive average estimations








) for atoms placed at different
topological distances 𝑑 ≤ 𝑘. In this first work, we calculated
only one type of 𝜆(𝑚
𝑖
) values. We calculated for all peptides
the average value 𝜒(𝑚
𝑖




atoms connected to the 𝑖th atom (𝑖 → 𝑗) and their




























We calculate the probabilities 𝑘𝑝(𝜆
𝑗
) for any atomic prop-
erty including 𝑘𝑝(𝜒
𝑗
) using a Markov Chain model for the
gradual effects of the neighboring atoms at different distances
in the molecular backbone. This method has been explained
in detail in many previous works so we omit the details here
[59].
2.2. Electronegativity Perturbation Model for Prediction of B-
Epitopes. Very recently Gonzalez-Diaz et al. [58] formulated
a general-purpose perturbation theory ormodel formultiple-
boundary QSPR/QSAR problems. We adapted here this new
theory or modeling method to approach to the peptide pre-
diction problem from the point of view of perturbation the-
ory. Let be a set of 𝑖th peptide molecules denoted as𝑚
𝑖
with a
value of efficiency 𝜀
𝑖𝑗
as epitopes experimentally determined










, . . . , 𝑐
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).
We put the main emphasis here on peptides reported in the
database IEDB. In this sense, the boundary conditions 𝑐
𝑗
used
here are the same reported in this database, 𝑐
0
= is the specific


















so is the organism that expresses the peptide (but it can
include also artificial peptides, cellular lines, etc.), ho is the
host organism exposed to the peptide by means of the bp
detected with tq. As our analysis, based on the data reported
by IEDB we are unable to work with continuous values of
epitope activity 𝜀
𝑖𝑗
. Consequently, we have to predict the
discrete function of B-epitope efficiency 𝜆(𝜀
𝑖𝑗
) = 1 for epit-




) = 0, otherwise.
Ourmain aim is to predict the shift or change in a function of




)ref − 𝜆(𝜀𝑖𝑗)new that takes
place after a change, variation, or perturbation (Δ𝑉) in the
structure and/or boundary conditions of a peptide of refer-
ence. But we know the efficiency of the process of reference
𝜆(𝜀
𝑖𝑗
)ref in addition to the molecular structure and the set of
conditions 𝑐
𝑗
for initial (reference) and final processes (new).
Consequently, to predict Δ𝜆(𝜀
𝑖𝑗
) we have to predict only
𝜆(𝜀
𝑖𝑗
)new the efficiency function of the new state obtained by
a change in the structure of the peptide and/or the boundary
conditions. Let Δ𝑉 be a perturbation in a function 𝜆; we can
define 𝑉
𝑖𝑗
as the state information function for the reference
and new states. According to our recent model [58], we can
write 𝑉
𝑖𝑗
as a function of the conditions and structure of the
peptide 𝑚
𝑖
as follows. In fact, the variational state functions
𝑉
𝑖𝑗
have to be written in pairs in order to describe the initial




































The state function 𝑛𝑉
𝑖𝑗
is for the 𝑖th peptide measured
under a set of 𝑐
𝑖𝑗
boundary conditions in output, final, or new
state.The conjugated state function 𝑟𝑉
𝑞𝑟
is for the 𝑞th peptide
measured under a set of 𝑐
𝑞𝑟
boundary conditions for the input,
initial, or reference state. The difference Δ𝑉 between the new








































Equation (3) described before opens the door to test
different hypothesis. A simple hypotheses is H
0
: existence of
one small and constant value of the perturbation function
Δ𝑉 = 𝑒
0
for all the pairs of peptides and a linear relationship
Table 1: Results of QSPR-perturbation model for IEDB B-Epitopes.
Data Stat. Pred. Predicted epitope perturbations
subset param. % 𝜆(𝜀𝑖𝑗) = 1 𝜆(𝜀𝑖𝑗) = 0
𝜆(𝜀
𝑖𝑗
) = 1 Sp 97.0 84607 2660
𝜆(𝜀
𝑖𝑗
) = 0 Sn 93.6 4354 63548
Total train Ac 95.5
𝜆(𝜀
𝑖𝑗
) = 1 Sp 97.1 28060 840
𝜆(𝜀
𝑖𝑗
) = 0 Sn 93.3 1485 20641
Total cv Ac 95.4
Bold font is used to highlight the number of cases correctly classified by the
model.





















































We can use elemental algebraic operations to obtain from
these equations an expression for efficiency as epitope of the
peptide 𝜆(𝜀
𝑖𝑗
)new. In this case, considering 𝑏𝑖𝑗 ≈ 𝑑𝑞𝑟, we can
obtain the different expressions; the last may be very useful











































































































































4 Journal of Immunology Research
Table 2: Average values and count of input-output cases for different
organisms, process, and techniques.
Source organism (so) 𝑁in 𝑁out
∗
𝜒
Homo sapiens 38920 39274 2.685
Plasmodium falciparum 10669 9446 2.704
Hepatitis C virus 9935 10239 2.683
Bos taurus 5671 5780 2.690
Canine parvovirus 5655 5637 2.693
Foot-mouth disease virus 4062 4176 2.676
Triticum aestivum 3769 3887 2.703
Bacillus anthracis 3602 3600 2.699
Human papillomavirus 3316 3414 2.693
Human herpesvirus 3026 3132 2.684
Gallus gallus 2850 2829 2.689
Arachis hypogaea 2648 2670 2.687
Mycobacterium tuberculosis 2637 2593 2.688
Clostridium botulinum 2588 2722 2.685
SARS coronavirus 2550 2704 2.686
Mus musculus 2334 2287 2.682
Hepatitis B virus 2007 2066 2.680
Helicobacter pylori 1958 1796 2.695
Hevea brasiliensis 1938 1958 2.697
Hepatitis E virus 1928 1941 2.685
Shigella flexneri 1878 1701 2.699
Dengue virus 2 1767 1828 2.679
Staphylococcus aureus 1757 1661 2.694
Treponema pallidum 1739 1755 2.691
Escherichia coli 1721 1678 2.689
Murine hepatitis virus 1575 1603 2.692
Haemophilus influenzae 1545 1587 2.695
Streptococcus mutans 1523 1537 2.697
Puumala virus (strain) 1505 1574 2.689
Chlamydia trachomatis 1402 1546 2.704
Human respiratory virus 1347 1398 2.682
Borrelia burgdorferi 1228 1237 2.698
Hepatitis delta virus 1182 1199 2.690
Streptococcus pyogenes 1181 1251 2.697
Porphyromonas gingivalis 1143 1085 2.688
Human enterovirus 1106 1132 2.689
Influenza A virus 1085 1086 2.687
Mycoplasma hyopneumoniae 1044 1024 2.695
Rattus norvegicus 1025 1039 2.689
Bordetella pertussis 1011 960 2.685
Human T-lymphotropic virus 996 1031 2.680
Anaplasma marginale 977 857 2.707
Measles virus strain 804 810 2.688
Fasciola hepatica 803 857 2.685
Neisseria meningitidis 789 853 2.696
Human poliovirus 766 780 2.690
Tityus serrulatus 764 775 2.680
Torpedo californica 752 788 2.687
Table 2: Continued.
Source organism (so) 𝑁in 𝑁out
∗
𝜒
Cryptomeria japonica 719 794 2.680
Mycobacterium bovis 717 733 2.688
Trypanosoma cruzi 691 777 2.704
Andes virus CHI-7913 679 687 2.690
Bovine papillomavirus 672 665 2.692
Human hepatitis 670 696 2.688
Leishmania infantum 659 735 2.688
Human parvovirus 649 691 2.683
Poa pratensis 648 664 2.692
Aspergillus fumigatus 642 709 2.677
Duck hepatitis 587 603 2.688
Olea europaea 571 577 2.692
Porcine reproductive 515 514 2.681
Fagopyrum esculentum 509 497 2.685
Juniperus ashei 505 568 2.672
Mycobacterium leprae 489 542 2.690
Glycine max 477 509 2.685
D. pteronyssinus 455 464 2.680
Plasmodium vivax 453 446 2.690
Chlamydophila pneumoniae 446 462 2.690
Pseudomonas aeruginosa 443 454 2.691
Vibrio cholera 427 426 2.694
Streptococcus sp. 426 425 2.691
Mycobacterium avium 425 415 2.689
Dermatophagoides farinae 410 390 2.693
Human coxsackievirus 406 392 2.694
Equine infectious virus 404 419 2.688
Babesia equi 383 371 2.696
Prunus dulcis 383 379 2.708
Human adenovirus 375 405 2.686
Theileria parva 366 371 2.713
Candida albicans 365 370 2.690
Porcine endogenous 355 351 2.692
Ovis aries 352 350 2.683
Chironomus thummi 347 338 2.691
Sus scrofa 343 362 2.686
Bovine leukemia virus 333 329 2.676
Ricinus communis 329 314 2.692
Androctonus australis 322 357 2.685
Renibacterium salmoninarum 319 350 2.690
Orientia tsutsugamushi 309 372 2.705
Anacardium occidentale 293 306 2.693
Conus geographus 289 295 2.660
Host organism (ho) 𝑁in 𝑁out
∗
𝜒
Homo sapiens 257293 91093 2.6856
Mus musculus 107867 51466 2.6873
Oryctolagus cuniculus 65053 31433 2.6900
Bos taurus 15333 2072 2.6909
Rattus norvegicus 9450 3562 2.6876
Aotus sp. 9044 3933 2.6879
Sus scrofa 7725 3464 2.6873
Gallus gallus 7507 997 2.6790
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Table 2: Continued.
Source organism (so) 𝑁in 𝑁out
∗
𝜒
Canis lupus 6604 3334 2.6906
Macaca mulatta 5261 2569 2.6993
Ovis aries 3953 1653 2.6836
Equus caballus 3943 2099 2.6842
Cavia porcellus 3458 1688 2.6833
Capra hircus 2182 1127 2.6830
Aotus nancymaae 1659 852 2.6837
Pan troglodytes 1614 732 2.6757
Marmota monax 1100 509 2.7011
Felis catus 901 279 2.6838
Myodes glareolus 814 388 2.6863
Anas platyrhynchos 688 342 2.6880
Homo sapiens (human) 508 270 2.6851
Trichosurus vulpecula 456 126 2.6921
Mesocricetus auratus 438 104 2.6909
Macaca cyclopis 382 193 2.6871
O. tshawytscha 333 159 2.6929
Macaca fuscata 188 100 2.6667
Cricetulus migratorius 171 142 2.7008
Camelus dromedarius 171 89 2.6886
Dicentrarchus labrax 121 55 2.6759
Macaca fascicularis 96 52 2.6793
Saimiri sciureus 92 44 2.6900
Canis familiaris 77 42 2.6850
Rattus rattus 72 31 2.6760
Callithrix pygmaea 67 30 2.6920
Chinchilla lanigera 41 24 2.6729
Aotus lemurinus 30 19 2.6860
Papio cynocephalus 27 13 2.7267
Aotus griseimembra 26 12 2.7000
Mustela vison 18 10 2.7000
Chlorocebus aethiops 15 10 2.6875
Bos indicus 13 4 2.6925
Oncorhynchus mykiss 10 4 2.6700
M. macquariensis 9 6 2.6600
Cricetulus griseus 8 4 2.6900
Aotus trivirgatus 7 4 2.7000
Process type (pt) 𝑁in 𝑁out
∗
𝜒
AID 111197 108536 2.6876
OOID 32419 32617 2.6868
OAID 19210 18954 2.6801
OOA 15863 16303 2.6902
NI 13430 15206 2.6845
EWEIR 4818 4864 2.6843
EEE 3113 3546 2.6906
OOD 2806 2799 2.6887
AICD 1077 1095 2.6812
EWED 696 686 2.6879
DEWED 280 337 2.6804
TT 260 215 2.6806
OOC 153 137 2.6800
Table 2: Continued.
Source organism (so) 𝑁in 𝑁out
∗
𝜒
Technique (tq) 𝑁in 𝑁out
∗
𝜒
ELISA 133458 135109 2.6871
WI 33627 33292 2.6887
ACAbB 7780 9068 2.6862
PhDIP 7450 4496 2.6771
RIA 5241 5218 2.6858
IFAIH 4454 4581 2.6879
NIAA 4222 4316 2.6892
FIA 2255 2276 2.6897
PAC 1312 1219 2.6837
IP 1127 1089 2.6886
SPR 758 639 2.6860
FACS 608 647 2.6907
Other 502 495 2.6813
SAC 484 393 2.6878
ELISPOT 396 412 2.6979
RDAT 366 323 2.6859
EDAT 284 330 2.6800
XRC 231 227 2.6880
MS 209 179 2.6849
PFF 171 153 2.6820
AbDPO 162 295 2.6968
CdC 146 205 2.6895
IAbBA 144 183 2.6940
IOT 124 106 2.6835
HAGGI 115 122 2.6834
IgMHR 89 90 2.6929
EAAA 84 139 2.6922
HS 82 67 2.6791
AbdCC 73 118 2.6897
AGG 50 60 2.6980
CM 50 57 2.6863
The ∗indicates that quantities like ∗𝜒 is the average value of the mean
electronegativity (𝑚𝑖) for all the peptides in IEDB that are epitopes for the
same boundary condition.
3. Results and Discussion
We propose herein, for the first time, a QSRR-perturbation
model able to predict variations in the propensity of a peptide
to act as B-epitope taking into consideration the propensity
of a peptide of reference and the changes in peptide sequence,
immunological process, host organism, source organisms,
and the experimental technique used. The best QSPR-









− 221.642 ⋅ Δ𝜒seq
+ 8.770 ⋅ ΔΔ𝜒ho + 63.572 ⋅ ΔΔ𝜒so
− 55.387 ⋅ ΔΔ𝜒ip + 201.919 ⋅ ΔΔ𝜒tq − 2.149,
𝑁 = 155169, 𝑅𝑐 = 0.92,
𝑈 = 0.15, 𝑝 < 0.01.
(6)
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The first input term is the value 𝜆(𝜀
𝑖𝑗
)ref is the scoring
function 𝜆 of the efficiency of the initial process 𝜀
𝑖𝑗
(known
solution). The function 𝜆(𝜀
𝑖𝑗
)ref = 1 if the 𝑖th peptide could
experimentally be demonstrated to be a B-epitope in the





)ref = 0 otherwise. The variational-perturbation
terms ΔΔ𝜒
𝑐𝑗
are at the same time terms typical of pertur-
bation theory and moving average (MA) functions used in
Box-Jenkin models in time series [60]. These new types of
terms account both for the deviation of the electronegativity
of all amino acids in the sequence of the new peptide
with respect to the peptide of reference and with respect
to all boundary conditions. In Table 1, we give the overall
classification results obtainedwith thismodel. Speck-Planche
et al. [61–63] introduced different multitarget/multiplexing
QSARmodels that incorporate this type of information based
on MAs. The results obtained with the present model are
excellent comparedwith other similarmodels in the literature
useful for other problems including moving average models
[64, 65] or perturbation models [58]. Notably, this is also the
first model combining both perturbation theory and MAs in
a QSPR context.
The other input terms are the following. The first Δ𝜒seq =
𝜒(𝑚
𝑞
)ref −𝜒(𝑚𝑖)new is the perturbation term for the variation
or in themean value of electronegativity for all amino acids in
the sequence of the peptide of reference. The remnant input
variables of the model ΔΔ𝜒
𝑐𝑗
= Δ𝜒












values of the conditions of the new assay 𝑐𝑗-new that represent
perturbations with respect to the initial conditions 𝑐
𝑖𝑗
-ref of










) for all new and reference peptides in IEDB that
are epitopes under the 𝑗th or 𝑟th boundary condition. The
values of these terms have been tabulated for >500 source
organisms, >50 host organisms, >10 biological process, and





) of the new and reference peptides and the




) for all combinations
of boundary conditions to predict the perturbations of the
action as epitope of peptides. In doing so we can found the
optimal sequence and boundary conditions towards the use
of the peptide in the development of a vaccine. In Table 2 we





In Table 3 we depict the sequences and input-output
boundary conditions for top perturbations present in IEDB.
All these perturbations have observed value of 𝜆(𝜀
𝑖𝑗
)new = 1
and predicted value also equal to 1 with a high probability.
See Supplementary Material available online at http://dx.doi
.org/10.1155/2014/768515 file contains a full list of >200,000
cases of perturbations.
4. Conclusions
It is possible to develop generalmodels for vaccine design able
to predict the results of multiple input-output perturbations
in peptide sequence and experimental assay boundary condi-
tions using ideas of QSPR analysis, perturbation theory, and
Box and Jenkins MA operators. The electronegativity values
calculated withMARCH-INSIDE seem to be goodmolecular
descriptors for this type of QSPR-perturbation models.
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[17] E. Estrada andH.González, “What are the limits of applicability
for graph theoretic descriptors in QSPR/QSAR? modeling
dipole moments of aromatic compounds with TOPS-MODE
descriptors,” Journal of Chemical Information and Computer
Sciences, vol. 43, no. 1, pp. 75–84, 2003.
[18] Y. Marrero-Ponce, J. A. Castillo-Garit, E. Olazabal et al., “Tom-
ocomd-Cardd, a novel approach for computer-aided “rational”
drug design: I. Theoretical and experimental assessment of a
promising method for computational screening and in silico
design of new anthelmintic compounds,” Journal of Computer-
Aided Molecular Design, vol. 18, no. 10, pp. 615–634, 2004.
[19] Y. Marrero Ponce, R. Medina Marrero, E. A. Castro et al., “Pro-
tein quadratic indices of the “macromolecular pseudograph’s 𝛼-
carbon atom adjacency matrix”. 1. prediction of arc repressor
alanine-mutant’s stability,”Molecules, vol. 9, no. 12, pp. 1124–1147,
2004.
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